Skip to content

Early Haemodynamic Optimization Using Preload Dependence During Septic Shock = EHOSS-1

Effect of Haemodynamic Optimization Using Preload Dependence Indexes and Pulmonary Thermodilution on Cardiovascular Failure Duration During Septic Shock: a Randomized Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01972828
Acronym
EHOSS-1
Enrollment
61
Registered
2013-10-31
Start date
2007-07-31
Completion date
Unknown
Last updated
2013-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock

Keywords

Septic shock, Randomized controlled trial, Preload dependence, Pulmonary thermodilution

Brief summary

Haemodynamic optimization is of paramount importance in septic shock, but is really consensual and standardized during the first 6 hours of treatment. Haemodynamic treatment including fluid loading management, vasoactive treatment and oxygen transport optimization is mainly based on expert recommendations or non-randomized trials. Recently, preload dependence indexes such as pulse pressure variation have been shown to be more accurate to predict fluid responsiveness than static indexes such as filling pressures. However, whether using preload dependence indexes changes septic shock prognostic remains to date unknown. The aim of this non-blinded randomized controlled trial is to assess whether haemodynamic optimization using preload dependence indexes and pulmonary thermodilution 1. reduces septic shock duration assessed by administration duration of vasoactive treatment (primary end point), 2. reduces regional hypoperfusion assessed by arterial lactate, 3. reduces lung hydrostatic oedema linked to excessive fluid loading (assessed by PaO2/FIO2 ratio and extravascular lung water). 4. reduces organ dysfunction (assessed by the SOFA score), ICU stay and 7 and 28 day mortality Control group is managed with an algorithm using filling pressures to drive haemodynamic treatment.

Interventions

DRUGFLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN ®)

in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.

DRUGSTANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN ®)

in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age over 18 years * and fulfilment of two of four criteria for the systemic inflammatory response syndrome * and systolic blood pressure no higher than 90 mm Hg (after a crystalloid-fluid challenge of 25 ml per kilogram of body weight over a 30-minute period) * and documented or suspected infection

Exclusion criteria

* delay between first observation of hypotension and inclusion above 12 hours * pregnancy * acute coronary syndrome * acute cerebral vascular event (\< 1 month), * contraindication to central venous catheterization in the superior vena cava territory * contraindication to femoral arterial catheterization * active haemorrhage * burn injury * trauma * requirement for immediate surgery (\< 6 hours) * acute pulmonary oedema of cardiogenic origin * do-not-resuscitate status, or advanced directives restricting implementation of the protocol. * Informed consent not obtained from the patient or surrogates * Patient already included in another therapeutic trial * patient previously included in the same therapeutic trial

Design outcomes

Primary

MeasureTime frameDescription
Time to septic shock resolution28 daysshock resolution is defined by vasopressor weaning

Secondary

MeasureTime frameDescription
mortality28 days
Ventilator free days28 days
number of days with hyperlactactatemia28 days
number of days with pulmonary edema28 joursassessed by transpulmonary thermodilution

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026